Crocs, Inc. vs Koninklijke Philips NV — how do they compare? Crocs, Inc. trades at $116.68 (market cap $5.53B), while Koninklijke Philips NV trades at $24.3 (market cap $23.68B). The key difference: Koninklijke Philips NV is far larger — about 4.3× Crocs, Inc.'s market cap, and Koninklijke Philips NV pays a 4.21% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Koninklijke Philips NV for 84 Days on average.
| CROX | PHG | |
|---|---|---|
Market Cap | $5.53B | $23.68B |
Volume | 967,176 | 1,443,075 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $32.91 |
52-Week Low | $73.39 | $23.81 |
Typical Hold Time | 96 Days | 84 Days |
Enterprise Value | $7.04B | $30.07B |
Dividend Yield | — | 4.21% |
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $116.84, down 2.81% today, amid bearish technical signals but strong fundamental valuation metrics. The stock shows attractive P/E of 10.23 and P/S of 1.46, with robust profitability margins including 57.47% gross margin and 42.3% ROE. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $4.55 surpassing the $4.35 estimate. The company maintains strong cash flow generation despite a net loss in 2025, with management focusing on product innovation and HEYDUDE brand repositioning.
CROX presents a compelling value opportunity with discounted valuation multiples relative to historical performance, though near-term technical weakness and competitive pressures warrant caution. Analyst consensus remains bullish with $136.78 price target representing 17% upside potential. Key risks include consumer discretionary spending sensitivity and execution challenges with brand diversification initiatives. The stock's current levels offer entry points for long-term investors seeking exposure to a profitable footwear company with strong brand recognition.
PHG trades at $24.30, up 0.62% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Analyst consensus leans Hold (63.64%) while institutional activity remains active with recent purchases by Bank of America and Arrowstreet Capital.
The outlook balances recovery momentum against technical weakness. Investment opportunity lies in continued earnings improvement and new product launches, while risks include competitive pressures and the bearish technical trend. Debt levels remain manageable with debt-to-asset ratio at 25.44% as of 2025.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →